Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities

Back

ESC Premium Access

Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities

Session: New concepts in pulmonary hypertension

Topic: Pulmonary Hypertension

Speaker: Professor S. Rosenkranz (Cologne, DE)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor Stephan Rosenkranz

Heart Center at the University of Cologne, Cologne (Germany)

29 presentations

9 followers

5 more presentations in this session

Validation of ESC/ERS 2015 guidelines risk score in patients with scleroderma associated pulmonary arterial hypertension (SSc-PAH)

Speaker: Doctor H. Fayed (London, GB)

Blood viscosity and its relevance to the diagnosis and management of pulmonary hypertension: a new elephant in the cathlab

Speaker: Doctor A. Kempny (London, GB)

Upfront triple combination therapy with ambrisentan, tadalafil and subcutaneous treprostinil in incident patients with severe pulmonary arterial hypertension

Speaker: Doctor M. D'Alto (Naples, IT)

Waitlist outcomes for Eisenmengers patients listed for bilateral sequential lung transplant or heart-lung transplant

Speaker: Doctor K. Kearney (Sydney, AU)

Efficacy of pulmonary hypertension-targeted drugs for severe chronic thromboembolic pulmonary hypertension

Speaker: Doctor K. Takeuchi (Tokyo, JP)

Access the full session

New concepts in pulmonary hypertension

Speakers: Professor S. Rosenkranz, Doctor H. Fayed, Doctor A. Kempny, Doctor M. D'Alto, Doctor K. Kearney...

Access

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources